Imatinib Mesylate Tablet, Film Coated
Product Images NDC 67877-633

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Imatinib Mesylate (NDC 67877-633). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ascend Laboratories, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Imatinib-bottle-100mg (Imatinib Bottle 100mg)

Each tablet contains 100 mg of imatinib free base. The usual dosage should be seen in the package insert. It should be stored between 15-30°C (59-86°F) with excursions permitted up to 25°C (77°F). It must be protected from moisture and dispensed in a tight container. This drug must be kept out of the reach of children. The information provided seems to be related to a drug sold in the form of 90 tablets distributed by "Ascend Laboratories, LLC ASC Parsany M) 07054 ASCEND am", with a code "TSDRUGSIEO1S".*

FDA Label Image

Imatinib-bottle-400mg (Imatinib Bottle 400mg)

Each tablet of this medication contains 400mg of imatinib. It comes in a package with Potieny NDC 67877-634-3. The usual dosage must be referred to the package insert. The medication should be kept at 25°C (77°F), with excursions allowed to 15-30°C (59-86°F), and should be protected from moisture. The medication should be dispensed in a tight container with a USP Controlled Room Temperature. The medication must be kept away from children, and it is only available through prescription (Rx Only). It is manufactured in India by Shilpa Medicare Limited, Jadcherla - 509 301, and distributed by Ascend Laboratories, LLC, Parsippany, NJ 07054.*

FDA Label Image

Imatinib-fig1 (Imatinib Fig1)

This is a figure displaying the progression-free survival for a clinical trial population. It includes hazard ratio, log-rank test, and time in months since randomization. The percentage of participants without progression is also displayed.*

FDA Label Image

Imatinib-fig2 (Imatinib Fig2)

The figure shows the time to progression to AP or BC for patients receiving Imatinib mesate and PNeARRC. The number of patients, hazae Raso, and Log-rank Test results are also provided. Patients were censored at discontinuation of treatment or last follow-up.*

FDA Label Image

Imatinib-struc (Imatinib Struc)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.